Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Alternative RNA Splicing

Alternative RNA Splicing

Alternative RNA splicing is the regulated splicing of exons and introns to produce different mature mRNAs from a single pre-mRNA. Unlike in constitutive splicing where a single gene produces a single type of mRNA, alternative splicing allows an organism to produce multiple proteins from a single gene and plays an important role in protein diversity.
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...

Alternative RNA Splicing

Alternative RNA Splicing

RNA Splicing

RNA Splicing

Splicing is the process by which eukaryotic RNA is edited before its translation into protein. The RNA strand transcribed from eukaryotic DNA is called the primary transcript. The primary transcripts that become mRNAs are called precursor messenger RNAs (pre-mRNAs). Eukaryotic pre-mRNA contains alternating sequences of exons and introns. Exons are nucleotide sequences that code for proteins, whereas introns are the non-coding regions. In RNA splicing, introns are removed and exons are bonded...

Pre-mRNA Processing: RNA Splicing

Pre-mRNA Processing: RNA Splicing

Point and Frameshift Mutations

Point and Frameshift Mutations

Point mutations are genetic alterations involving the change of a single nucleotide base pair in DNA. Depending on how the alteration affects protein synthesis, they can lead to various consequences.Point mutations fall into the following types:Silent mutations occur when a nucleotide change does not alter the amino acid sequence due to the redundancy of the genetic code. For instance, changing ACC to ACA still encodes threonine, leaving the protein function unaffected. This occurs because...

Long-patch Base Excision Repair

Long-patch Base Excision Repair

Since the discovery of the two BER pathways, there has been a debate about how a cell chooses one pathway over the other and the factors determining this selection. Numerous in vitro experiments have pointed out multiple determinants for the sub-pathway selection. These are:

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Altered dorsal striatal subregional connectivity associated with distinct executive function deficits in first-episode, drug-naïve major depressive disorder: Evidence from functional connectivity and granger causality analysis.

Progress in neuro-psychopharmacology & biological psychiatry·2026

Same author

Research on the Purchase Behavior of Owner-Pet Matching Outfits Based on the Extended Theory of Planned Behavior.

Behavioral sciences (Basel, Switzerland)·2026

Same author

Pain control or brain protection with esketamine: a reply.

Anaesthesia·2026

Same author

Exploring predictors of low nutritional literacy in maintenance hemodialysis patients: a machine learning and network analysis approach.

Frontiers in public health·2026

Same author

Fate induction through asymmetric T cell division is modulated by chimeric antigen receptor costimulatory domains.

Nature immunology·2026

Same author

Expression dynamics during metamorphosis and genome-wide analysis of the myosin gene family in the Chinese mitten crab (Eriocheir sinensis).

BMC genomics·2026

Search research articles

Related Experiment Video

Updated: Nov 1, 2025

Detection of Alternative Splicing During Epithelial-Mesenchymal Transition

Detection of Alternative Splicing During Epithelial-Mesenchymal Transition

Published on: October 9, 2014

Splicing factor mutations in hematologic malignancies.

Sisi Chen¹, Salima Benbarche¹, Omar Abdel-Wahab^1,2

¹Human Oncology and Pathogenesis Program and.

|June 22, 2021

Summary

This summary is machine-generated.

Mutations in RNA splicing factors drive myeloid and lymphoid cancers by altering RNA processing. These genetic changes create new therapeutic targets currently in early clinical trials.

More Related Videos

Engineering Artificial Factors to Specifically Manipulate Alternative Splicing in Human Cells

Engineering Artificial Factors to Specifically Manipulate Alternative Splicing in Human Cells

Published on: April 26, 2017

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models

Published on: December 9, 2016

Related Experiment Videos

Last Updated: Nov 1, 2025

Detection of Alternative Splicing During Epithelial-Mesenchymal Transition

Detection of Alternative Splicing During Epithelial-Mesenchymal Transition

Published on: October 9, 2014

Engineering Artificial Factors to Specifically Manipulate Alternative Splicing in Human Cells

Engineering Artificial Factors to Specifically Manipulate Alternative Splicing in Human Cells

Published on: April 26, 2017

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models

Published on: December 9, 2016

Area of Science:

Hematology
Molecular Biology
Oncology

Background:

Mutations in RNA splicing factors are common in myeloid neoplasms, lymphoproliferative disorders, and clonal hematopoiesis.
Aberrant RNA splicing is implicated in the development of these clonal hematopoietic conditions.
Specific mutations can alter splicing in ways beyond simple loss of function.

Purpose of the Study:

To review the molecular effects of splicing factor mutations on RNA splicing.
To elucidate the mechanisms by which these mutations drive clonal transformation of hematopoietic cells.
To discuss the development of novel therapeutics targeting these mutations in hematologic malignancies.

Main Methods:

Review of molecular effects of splicing factor mutations.
Analysis of mechanisms driving clonal hematopoietic transformation.
Examination of therapeutic strategies targeting splicing factor mutations.

Main Results:

Splicing factor mutations lead to aberrant mRNA species with potential roles in disease pathogenesis.
Cells with these mutations exhibit sensitization to further perturbations of the splicing machinery.
Novel therapeutic approaches targeting these mutations are under investigation in early-phase clinical trials.

Conclusions:

Splicing factor mutations are key drivers in various hematologic malignancies.
Understanding these mutations opens new research avenues into disrupted biological pathways.
Targeted therapies are emerging as a promising treatment strategy for these genetically defined patient subsets.